Juvenile Arthritis News

Disparities in lupus ICU admission and renal outcomes between Black and white children are greater in children’s hospitals serving more Black patients, according to data published in Arthritis Care & Research.

The FDA has approved Tyenne, the second tocilizumab biosimilar overall and the first available in both intravenous and subcutaneous formulations, according to a press release from its manufacturer.

The U.S. Department of Veterans Affairs will replace Humira with the biosimilar Hadlima on its national formulary, according to a press release from Organon, which markets biosimilar.

Apoptotic lymphocytes in peripheral blood may be a meaningful factor in the prognosis of juvenile-onset systemic lupus erythematosus, as well as a predictor of disease activity, according to data published in Pediatric Rheumatology.

A lot can change in a year. But has it?

Multidisciplinary strategies combining physical and psychological strategies were the most effective for patients with hypermobility spectrum disorders or Ehlers-Danlos syndrome, according to a systematic review.

Celltrion USA has submitted a Biologics License Application to the FDA for its tocilizumab biosimilar candidate CT-P47, according to a press release.

An initiative to switch clinically stable patients from Remicade to a biosimilar significantly increased biosimilar use in rheumatology and gastroenterology clinics within the University of North Carolina health system, according to data.

Children with obesity demonstrate a greater likelihood of shock, ICU admission and worse laboratory scores in multisystem inflammatory syndrome, but not Kawasaki disease, according to data published in JAMA Network Open.

CVS Caremark, one of the nation’s largest pharmacy benefit managers, will remove Humira from its major national commercial formularies effective April 1 in favor of biosimilar options, according to a press release from the company.